Comparative Pharmacology
Head-to-head clinical analysis: QUALAQUIN versus QUINAGLUTE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: QUALAQUIN versus QUINAGLUTE.
QUALAQUIN vs QUINAGLUTE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Quinine is a cinchona alkaloid that acts as a blood schizonticide against Plasmodium species. It inhibits heme polymerase in the parasite, leading to accumulation of toxic heme and parasite death. It also has weak gametocytocidal activity against P. vivax and P. malariae.
Class Ia antiarrhythmic agent; binds to sodium channels and inhibits the fast inward sodium current, slowing phase 0 depolarization and prolonging the action potential duration. Also exhibits anticholinergic and negative inotropic effects.
325-650 mg orally every 6 hours as needed for pain; maximum 2.6 g/day.
324-648 mg orally every 8-12 hours; extended-release formulation (quinidine gluconate).
None Documented
None Documented
Terminal elimination half-life approximately 8 hours in healthy adults; prolonged in hepatic impairment (up to 12-18 hours) and severe malaria (up to 14-20 hours).
Terminal elimination half-life is 5-7 hours in adults with normal renal function. In hepatic impairment, half-life may increase to 12-24 hours; in severe renal impairment (CrCl <10 mL/min), half-life may exceed 24 hours.
Renal (approximately 20% unchanged; remainder as metabolites); biliary/fecal (minor).
Renal elimination of unchanged drug and metabolites accounts for approximately 60-70% of total clearance. Biliary/fecal excretion contributes about 20-30%. Acidic urine increases renal clearance.
Category C
Category C
Antiarrhythmic (Class Ia)
Antiarrhythmic (Class Ia)